Entrada Therapeutics (TRDA) Consolidated Net Income (2022 - 2025)
Historic Consolidated Net Income for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$44.2 million.
- Entrada Therapeutics' Consolidated Net Income fell 21575.19% to -$44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.5 million, marking a year-over-year decrease of 28829.49%. This contributed to the annual value of $65.6 million for FY2024, which is 108780.3% up from last year.
- According to the latest figures from Q3 2025, Entrada Therapeutics' Consolidated Net Income is -$44.2 million, which was down 21575.19% from -$43.1 million recorded in Q2 2025.
- Entrada Therapeutics' Consolidated Net Income's 5-year high stood at $55.0 million during Q2 2024, with a 5-year trough of -$44.2 million in Q3 2025.
- Moreover, its 4-year median value for Consolidated Net Income was -$17.3 million (2025), whereas its average is -$9.4 million.
- Per our database at Business Quant, Entrada Therapeutics' Consolidated Net Income surged by 44948.68% in 2024 and then plummeted by 21575.19% in 2025.
- Entrada Therapeutics' Consolidated Net Income (Quarter) stood at -$24.6 million in 2022, then soared by 61.43% to -$9.5 million in 2023, then surged by 111.63% to $1.1 million in 2024, then plummeted by 4098.19% to -$44.2 million in 2025.
- Its Consolidated Net Income stands at -$44.2 million for Q3 2025, versus -$43.1 million for Q2 2025 and -$17.3 million for Q1 2025.